Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SSGJ-601 in Diabetic Macular Edema
NCT04151407Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of 601 in diabetic macular edema (DME) (7 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
601
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04151407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151407.